查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863278

勃起功能障碍治疗设备市场按产品类型、适应症、年龄层、材质、作用机制、电源、最终用户和分销管道划分－2025年至2032年全球预测

Erectile Dysfunction Devices Market by Product Type, Indication, Age Group, Material Type, Mechanism of Action, Power Source, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，治疗勃起功能障碍的设备市场将成长至 28 亿美元，复合年增长率为 6.35%。

关键市场统计数据
基准年 2024 17.1亿美元
预计年份：2025年 18.1亿美元
预测年份 2032 28亿美元
复合年增长率 (%) 6.35%

全面概述了当前治疗勃起功能障碍的器械领域，重点介绍了技术进步、相关人员的需求以及不断发展的患者照护路径。

引言部分将当前勃起功能障碍治疗器材的现状置于快速的临床创新、不断变化的医保报销模式以及患者对微创解决方案日益增长的期望等背景下进行阐述。近年来，技术进步拓展了治疗选择，使其不再局限于第一线药物治疗，而是为植入式解决方案、辅助性功能增强装置和非侵入性治疗方法创造了空间。同时，以病人为中心的治疗路径也日益受到重视，便利性、隐密性和生活品质的提升成为推动治疗方案普及的关键因素。

临床、生产和分销管道的相关人员正面临着一个动态变化的环境，监管政策的清晰度和支付方的政策日益影响着产品设计和上市策略。临床医生会仔细检视产品的耐用性、併发症发生率和功能性结果，而采购团队则需要在设备效能、库存和训练成本之间取得平衡。同时，患者越来越多地参与治疗方案的选择中，优先考虑那些符合自身生活方式且安全性已得到验证的设备。在此背景下，市场在多个维度上呈现日益明显的差异化，包括设备的作用机制、材质成分、动力来源和终端用户环境，这些因素正在塑造产品的市场接受度和竞争定位。

这份介绍简报阐明了製造商和投资者需要将临床证据、设计创新和商业性执行结合的必要性。透过将产品属性与实际治疗路径和分销情况联繫起来，企业可以更好地优先分配研发资源，并打入市场策略。

临床创新、监管调整和分销管道转型将如何整合，从而重新定义勃起功能障碍医疗器材生态系统的价值创造？

该领域的变革性变化是由临床、技术和市场力量的融合所驱动的，重新定义了价值创造。在临床上，微创和可逆治疗方法的兴起凸显了低强度超音波和衝击波疗法等治疗设备的重要性，这些设备提供了非手术治疗途径，使更多患者受益。同时，植入设计的创新（包括充气式和半刚性植入的改进）优先考虑可靠性、易于植入性和患者舒适度。这些技术进步日益受到材料科学发展的影响，包括弹性聚合物、硅酮、不銹钢和钛等金属合金以及兼俱生物相容性和机械功能的聚氨酯配方。

从监管和报销的角度来看，更清晰的证据标准和基于价值的采购讨论正鼓励製造商在研发早期阶段就提供疗效和耐久性方面的比较数据。这种转变有利于那些能够证明其产品在主要适应症、次要适应症和多适应症（包括老龄化相关、神经系统、血管、内分泌和心理因素等病因）方面均取得显着疗效的公司。同时，分销管道的演变正在改变市场准入模式。线上平台降低了消费者参与的门槛，而传统的专科零售商和医院采购系统在复杂器械和手术方面仍然发挥着重要作用。这些趋势正在促使医疗设备製造商、临床相关人员和分销合作伙伴之间建立策略联盟，以在控製成本和复杂性的同时加速产品推广应用。

从本质上讲，市场格局正在从以产品为中心的提案转向综合护理解决方案，其中证据、可用性和分销策略共同决定了商业性成功。

评估2025年美国关税对医疗设备供应链和定价策略的累积营运、商业和采购影响

2025年实施的定向关税迫使相关人员重新评估其供应链结构、筹资策略和成本转嫁动态。依赖跨境零件的製造商，尤其是那些生产精密植入和电疗设备的製造商，正面临不断上涨的投入成本和日益复杂的物流挑战。为此，一些製造企业正在评估回流、近岸外包或多源采购等策略，以降低关税风险，同时确保品管和合规性。拥有一体化製造地和完善品质系统的策略供应商则更有能力应对和管理关税波动，而不会影响产品的连续性。

除了製造业之外，关税也影响分销通路的经济效益和定价策略。零售商和专业分销商必须权衡利润压力与市场竞争地位，在某些情况下，他们需要重新谈判供应商合约并整合库存单位（SKU），以维持存货周转和价格稳定。医院和专科诊所正在修订采购标准，更加重视整体拥有成本和长期服务协议，而非仅依赖单价，减轻临时关税上调带来的预算影响。此外，不断变化的政策环境正在加速有关双边供应商协议和战略库存缓衝的讨论，以确保择期手术的连续性。

尤其值得注意的是，关税环境凸显了供应商可追溯性和零件采购路径在监管文件中透明化的重要性。积极记录其供应链韧性、实施双重采购策略并向支付机构和采购利益相关人员传达成本管理计划的公司，将更有利于应对不确定性并维持市场进入。

细分市场分析洞察：揭示分销管道对产品差异化、适应症复杂性、人口统计因素、材料选择、作用机制选择和策略定位的影响

细分市场分析揭示了产品差异化的多面性，以及研发和商业化与临床及终端用户需求保持一致的重要性。依产品类型划分，市场可分为阴茎植入、辅助器具、治疗装置和真空压迫装置。阴茎植入本身又可分为植入，两者在机械复杂性、病患满意度和手术训练要求方面各有优劣。辅助器具分为夹式和环式压迫装置，与植入相比，通常定位为辅助治疗或微创治疗方案。治疗装置包括低强度脉衝超音波设备和衝击波治疗装置，这些装置无需植入，专注于再生医学，旨在治疗潜在的血管和组织疾病。

基于适应症的细分提供了更细緻的视角。必须从混合型、原发性和续发性勃起功能障碍的角度来理解市场。混合型勃起功能障碍通常涉及老龄化相关因素和复杂的原因，需要多学科联合治疗。原发性勃起功能障碍通常由神经系统和血管因素引起，需要不同的治疗强度和实证标准。次发性勃起功能障碍包括荷尔蒙和心理因素，器械治疗策略通常需要与药物和行为介入结合。年龄层（青年、中年、61岁以上）决定了产品的定位、对侵入性的接受度以及对产品寿命和维护的期望。

对材料和作用机制的考量是决定器械性能和监管审批的关键。材料类型包括弹性聚合物、金属材料（如不銹钢和钛）、聚氨酯和硅胶，每种材料都有不同的生物相容性和机械性能。作用机制区分了液压装置和机械装置，而动力来源（电池供电与手动）的差异会影响易用性、维护和临床支援需求。最后，终端用户环境和分销管道（居家医疗、医院、专科诊所、线上平台、零售药局以及包括专科医疗设备和外科用品商店在内的专业零售商）的特征会影响产品的采用路径、培训需求和上市后支援义务。整合这些细分因素有助于发现有针对性的创新和客製化商业策略的机会，从而更好地反映临床实际情况和患者偏好。

区域绩效和策略要务（美洲、欧洲、中东和非洲、亚太地区）则着重于采用趋势、报销趋势和供应方面的考量因素

区域趋势差异显着，因此美洲、欧洲、中东和非洲以及亚太地区需要采取不同的商业和监管策略。在美洲，完善的报销系统和强大的医院主导手术基础有利于高复杂度植入方案的推广，尤其是在疗效持久且临床医生技术娴熟的情况下，这些方案更容易被接受。同时，直接面向消费者的销售管道以及对非侵入性治疗方案日益增长的需求，正在扩大门诊和居家治疗的患者群体。这为那些既能减轻手术负担又能维持临床疗效的价值提案创造了空间。

欧洲、中东和非洲地区（EMEA）的医保报销环境和监管流程各不相同，因此需要针对每个市场制定相应的证据支持和定价策略。在该地区，一些市场拥有先进的医疗保健体系，在提供充分的卫生经济学证据后，能够支持创新型治疗器械；而另一些市场则对价格较为敏感，更倾向于选择结构相对简单、成本可预测的器械。与当地经销商以及在采购体系和临床实践模式方面具有影响力的临床意见领袖伙伴关係，对于建立信誉和促进市场准入至关重要。

亚太地区正经历高所得市场快速普及和新兴经济体需求不断增长的双重局面。在许多市场，私人医疗服务的扩张和消费者健康素养的提高，为植入式和非侵入式医疗器材都创造了机会。然而，製造商必须应对不同的监管要求、当地的生产预期以及不同的临床实践模式。在整个亚太地区，临床证据、报销政策和分销网络的策略性整合将决定医疗器材普及的速度和规模。

成熟製造商、专业创新者和分销合作伙伴之间的竞争动态和企业策略驱动着产品系列、市场准入和临床应用。

竞争格局呈现出成熟医疗设备製造商、专业创新企业和新兴技术供应商并存的局面。主要企业透过临床证据的累积、丰富的产品系列组合以及通路伙伴关係，在其核心市场保持着强劲的竞争力。关键的企业策略包括：迭代式产品开发以降低手术复杂性；材料创新以提高生物相容性和耐久性；以及透过有针对性的研究者主导试验和真实世界结果註册研究来培养临床领导者。

对于那些寻求利用外部材料科学、电子学和治疗能量技术等专业知识来补充自身能力的公司而言，战略联盟和许可协议十分常见。能够整合售后服务模式（例如培训项目、外科医生支援和产品保固）的公司，能够在初始销售之后实现可持续的差异化优势。此外，将与医院的直接关係与专业零售和线上通路结合的分销策略，有助于扩大产品在各种终端用户环境中的覆盖范围。

併购和少数股权投资仍然是获取能力和加速市场准入的有效途径，尤其是在涉及新型治疗机制和数位健康相关技术时。那些保持临床结果透明、投资与支付方合作并根据不断变化的贸易政策调整製造地的公司，更有可能获得竞争优势。最终，公司的成功取决于其能否将创新产品线与切实可行的商业化计画和稳健的供应链结构结合。

为製造商、临床医生和通路合作伙伴提供切实可行的优先建议，以加速临床应用、增强市场进入并降低商业风险。

产业领导者应优先采取一系列切实可行的措施，将洞察转化为可衡量的商业性成果。首先，投资于对比临床证据和真实世界註册研究，以证明器械在主要适应症、次要适应症和混合适应症中的耐用性、功能性结果和併发症情况。此类证据对于说服支付方和临床医生，以及在医院采购过程中区分不同器材至关重要。其次，实现生产和供应商网路多元化，以降低关税波动和单一来源依赖的风险，同时建立可追溯性和品管体系，用于监管申报。

第三，根据特定的人口统计和临床细分市场，量身定制产品系列和商业化计划，因为年龄层、功能障碍病因和最终用户环境都会显着影响器械的选择。同时，优化材料和机制的选择，以平衡性能、成本和监管风险。第四，制定混合通路策略，将与医院的伙伴关係（用于复杂手术）与线上平台和专业零售商（用于微创解决方案和病患教育）结合。第五，儘早与支付方和卫生技术评估机构接洽，使证据生成与报销标准保持一致，并探索反映长期价值而非仅仅初始成本的创新支付模式。

最后，我们正在建立一个适应性强的商业模式，整合了临床医生培训、保固和服务以及数位化支援工具，旨在改善手术效果和患者满意度。这些措施将强化产品定位，减少商业性摩擦，并加速永续推广应用。

一套透明的调查方法，详细阐述了资料来源、专家检验、分析框架、情境测试以及已知的局限性，从而为医疗设备市场提供可靠的洞察。

本分析的调查方法结合了第一手和第二手资料收集、结构化的分析框架以及与临床和商业专家的反覆检验。第一手资料包括对临床医生、采购人员、分销商和技术开发人员的访谈，旨在收集有关医疗设备性能、推广障碍和分销管道趋势的经验性见解。第二手资料来源包括同行评审的临床文献、监管指导文件、材料科学研究和已发表的政策分析，以对临床和安全证据进行三角验证。

此分析方法采用多维度细分映射，涵盖产品、适应症、人口统计特征、成分、作用机制、动力来源、最终用户和分销管道等多个方面，以识别高潜力交叉领域。情境分析用于压力检验供应链和关税对业务连续性和采购行为的影响。此调查方法强调假设的透明度，并在结论取决于可变输入值时进行敏感度分析。研究结果会与独立的临床顾问和行业从业人员进行反覆检验，以确保其实际意义并完善解释。

此调查方法存在一些局限性，例如区域医保报销环境的差异以及新治疗方法临床证据的不断更新。在适当情况下，我们会指出资料缺口，并建议优先进行证据生成活动，以加强未来的评估。

整合市场驱动因素、结构性风险和策略重点，为业务决策、投资选择和产品蓝图图制定提供资讯。

总之，勃起功能障碍医疗器材市场正处于转折点，临床创新、材料科学、监管环境以及不断演变的通路共同构成了战略要务。能够整合可靠的实证医学证据、强大的生产平台和客製化分销策略的製造商，将更有利于把产品创新转化为永续的商业性成功。关注患者偏好、人口趋势和特定适应症的需求，将进一步提升产品与市场的契合度，并推动差异化价值提案。

监管政策的清晰度和支付方的合作仍然是提高产品普及率的关键基础，尤其对于高度复杂的植入解决方案和新型治疗方法更是如此。关税环境和分销经济的变化凸显了灵活的供应链结构和透明的成本管理策略的重要性。最终，能否在这个市场取得成功取决于能否将临床验证、业务永续营运和市场推广可行性整合起来，从而为患者带来可验证的疗效，并为医疗保健系统创造可预测的价值。

采用严谨的、以证据主导的产品开发和商业化方法的组织，将在不同的地理和医疗保健环境中创造机会，为在快速发展的治疗领域取得长期领先地位奠定基础。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 穿戴式神经调节设备在勃起功能障碍治疗的应用日益广泛
  • 消费保健Start-Ups正大力投资家用衝击波治疗设备。
  • 推出客製化3D列印阴茎支撑和真空疗法配件
  • 将人工智慧诊断技术融入居家勃起功能障碍治疗
  • 消费者对非侵入性电磁刺激解决方案的需求日益增长
  • 提高患者依从性的智慧PDE5抑制剂经皮吸收贴片的进展
  • 扩展数位健康平台，提供虚拟咨询和设备追踪功能
  • 透过泌尿系统诊所和远端医疗服务之间的合作，促进设备可近性
  • 在真空竖立装置的製造过程中，重点使用环保和可回收材料。
  • 采用区块链技术提升勃起功能障碍治疗设备中的病患资料安全

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型分類的勃起功能障碍治疗设备市场

  • 阴茎植入
    • 充气式植入
    • 半刚性植入
  • 辅助器具
    • 夹紧装置
    • 环形压缩装置
  • 治疗设备
    • 低强度脉衝超音波设备
    • 衝击波治疗设备
  • 真空压缩装置

第九章 依适应症分類的勃起功能障碍治疗器材市场

  • 混合型勃起功能障碍
    • 老龄化相关因素
    • 复杂原因
  • 原发性功能障碍
    • 神经系统因素
    • 血管因素
  • 次发性功能障碍
    • 荷尔蒙因素
    • 心理因素

第十章 按年龄组别分類的勃起功能障碍治疗设备市场

  • 18至40岁
  • 41至60岁
  • 61岁或以上

第十一章 按材料类型分類的勃起功能障碍治疗器械市场

  • 由弹性体製成
  • 由金属製成
    • 不銹钢
    • 钛
  • 聚氨酯
  • 硅酮

第十二章：依作用机转分類的勃起功能障碍治疗器材市场

  • 油压装置
  • 机械执行器

第十三章 按电源分類的勃起功能障碍治疗设备市场

  • 电池供电
  • 手动输入

第十四章 依最终使用者分類的勃起功能障碍治疗设备市场

  • 居家医疗
  • 医院
  • 专科诊所

第十五章 勃起功能障碍治疗器材市场（依通路划分）

  • 线上平台
  • 零售药房
  • 专业零售商
    • 医疗设备专卖店
    • 外科用品商店

第十六章 勃起功能障碍治疗器材市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 勃起功能障碍治疗器材市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 各国勃起功能障碍治疗器材市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Advin Health Care
    • Alma Lasers Ltd.
    • Augusta Medical Systems LLC
    • Boston Scientific Corporation
    • Coloplast A/S
    • Comphya SA
    • DirexGroup
    • Dornier MedTech GmbH
    • Futura Medical Developments Limited
    • G.SURGIWEAR LTD.
    • Implantica Management AG
    • Medispec Ltd.
    • OHHMED Medical Ltd.
    • Owen Mumford Limited
    • PROMEDON GmbH
    • Rigicon, Inc.
    • STORZ MEDICAL AG
    • TE Inc.
    • TIMM Medical
    • Vacurect
    • Zimmer MedizinSysteme GmbH
    • ZSI Surgical Implants SRL
Product Code: MRR-1730A405FA49

The Erectile Dysfunction Devices Market is projected to grow by USD 2.80 billion at a CAGR of 6.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.71 billion
Estimated Year [2025] USD 1.81 billion
Forecast Year [2032] USD 2.80 billion
CAGR (%) 6.35%

Comprehensive overview of the current erectile dysfunction device landscape highlighting technological progress, stakeholder needs, and evolving patient care pathways

The introduction situates the current erectile dysfunction device landscape within a context of rapid clinical innovation, shifting reimbursement paradigms, and amplified patient expectations for minimally invasive solutions. Over recent years, technological advances have expanded the therapeutic toolkit beyond pharmacologic first-line therapies, creating room for implantable solutions, supportive devices that enhance sexual function, and noninvasive therapeutic modalities. These developments have coincided with a rising emphasis on patient-centered pathways, where convenience, discreet use, and quality-of-life outcomes drive adoption.

Stakeholders across clinical, manufacturing, and distribution channels are navigating a dynamic environment in which regulatory clarity and payor policies increasingly influence product design and go-to-market strategies. Clinicians are scrutinizing evidence of durability, complication rates, and functional outcomes, while procurement teams balance device performance with inventory and training costs. At the same time, patients are more engaged in treatment selection, valuing devices that align with lifestyle preferences and have transparent safety profiles. Against this backdrop, the market is differentiating along several dimensions including device mechanism, material composition, power source, and end-user context, all of which shape adoption patterns and competitive positioning.

This introductory synthesis establishes the imperative for manufacturers and investors to align clinical evidence, design innovation, and commercial execution. By connecting product attributes to real-world clinical pathways and distribution realities, organizations can better prioritize R&D resources and market entry tactics that resonate with both clinicians and patients.

How clinical innovation, regulatory recalibration, and shifting channel dynamics are converging to redefine value creation across the erectile dysfunction device ecosystem

Transformative shifts in this segment are driven by a convergence of clinical, technological, and market forces that are redefining value creation. Clinically, the movement toward minimally invasive and reversible solutions has elevated the importance of therapeutic devices such as low-intensity pulsed ultrasound and shockwave therapy, which offer non-surgical pathways and an expanded addressable patient base. Concurrently, innovations in implant design, including refinements in inflatable and semi-rigid implants, have prioritized reliability, ease of implantation, and patient comfort. These technical upgrades are increasingly influenced by material science advances across elastomeric polymers, silicones, metallic alloys such as stainless steel and titanium, and polyurethane formulations that balance biocompatibility with mechanical function.

From a regulatory and reimbursement perspective, clearer evidence thresholds and value-based procurement discussions are prompting manufacturers to generate comparative effectiveness and durability data earlier in development. This shift favors companies that can demonstrate meaningful outcomes across primary, secondary, and mixed indications, including aging-related, neurological, vascular, hormonal, and psychogenic etiologies. At the same time, distribution and channel evolution is reshaping access models: online platforms are lowering barriers to consumer engagement, while traditional specialist retailers and hospital procurement systems maintain their role for complex devices and procedures. Together, these dynamics are encouraging strategic partnerships between device makers, clinical stakeholders, and distribution partners to accelerate adoption while controlling cost and complexity.

In essence, the landscape is moving from product-centric propositions to integrated care solutions where evidence, usability, and channel strategy converge to determine commercial success.

Assessing the cumulative operational, commercial, and procurement impacts of United States tariffs implemented during 2025 on device supply chains and pricing strategies

The introduction of targeted tariff measures in 2025 has prompted stakeholders to reassess supply chain architecture, sourcing strategies, and cost pass-through dynamics. Manufacturers reliant on cross-border components, particularly for precision-engineered implants and electronic therapeutic devices, have faced elevated input costs and logistical complexity. In response, several manufacturing organizations are evaluating reshoring, nearshoring, or multi-sourcing approaches to mitigate tariff exposure while preserving quality control and regulatory compliance. Strategic suppliers with integrated manufacturing footprints and established quality systems have an advantage in absorbing or managing tariff volatility without compromising product continuity.

Beyond manufacturing, tariffs have influenced channel economics and pricing strategies. Retailers and specialty distributors have needed to balance margin pressures with competitive positioning, leading some to renegotiate supplier contracts or consolidate SKUs to maintain inventory turnover and price stability. Hospitals and specialty clinics are recalibrating procurement criteria to emphasize total cost of ownership and long-term service agreements, rather than unit price alone, to shield budgets from episodic tariff-driven spikes. Additionally, the policy environment has accelerated dialogues around bilateral supplier agreements and strategic inventory buffers to ensure continuity of care for elective procedures.

Critically, the tariff environment has reinforced the importance of transparent supplier traceability and component provenance for regulatory submissions. Companies that proactively document supply chain resilience, implement dual-sourcing strategies, and communicate cost management plans to payors and procurement stakeholders are better positioned to navigate uncertainty and preserve market access.

Segment-driven insights revealing product differentiation, indication complexity, demographic drivers, material selection, mechanism choices, and channel implications for strategic positioning

Segmentation insights reveal the multifaceted nature of product differentiation and the importance of aligning R&D and commercialization with clinical and end-user needs. When evaluating products by type, the landscape encompasses penile implants, supportive devices, therapeutic devices, and vacuum constriction devices. Penile implants themselves bifurcate into inflatable implants and semi-rigid implants, each presenting distinct trade-offs between mechanical complexity, patient satisfaction, and surgical training requirements. Supportive devices are categorized into clamping devices and ring constriction devices, which are generally positioned as adjunctive or less invasive options relative to implants. Therapeutic devices include low-intensity pulsed ultrasound devices and shockwave therapy devices that offer non-implantable, regenerative-focused modalities targeting underlying vascular or tissue conditions.

Indication-based segmentation adds further nuance. The market must be understood across mixed erectile dysfunction, primary erectile dysfunction, and secondary erectile dysfunction. Mixed erectile dysfunction frequently involves aging-related causes as well as combination etiologies that require blended treatment pathways. Primary erectile dysfunction is often driven by neurological and vascular causes that necessitate different therapeutic intensities and evidence thresholds. Secondary erectile dysfunction encompasses hormonal and psychogenic causes where device strategies often intersect with pharmacologic and behavioral interventions. Age group stratification-encompassing younger adult populations, middle-aged cohorts, and those 61 years and above-informs product positioning, tolerance for invasiveness, and expectations around longevity and maintenance.

Material and mechanism considerations are central to device performance and regulatory review. Material types span elastomeric polymers, metallic materials such as stainless steel and titanium, polyurethane, and silicone, each bringing distinct biocompatibility and mechanical properties to bear. Mechanisms of action contrast hydraulic action devices with mechanical action devices, and power-source differentiation between battery-powered and manual units affects usability, maintenance, and clinical support requirements. Finally, end-user context and distribution channel dynamics-home healthcare, hospitals, specialty clinics, online platforms, retail pharmacies, and specialist retailers including medical device stores and surgical supply stores-shape adoption pathways, training needs, and post-market support obligations. Synthesizing these segmentation layers highlights opportunities for targeted innovation and tailored commercial strategies that reflect clinical realities and patient preferences.

Regional performance and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption trends, reimbursement dynamics, and supply considerations

Regional dynamics vary substantially and mandate differentiated commercial and regulatory strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement frameworks and a strong hospital-driven procedural base favor higher-complexity implantable solutions, particularly where durable outcomes and clinician familiarity reduce adoption friction. At the same time, direct-to-consumer channels and an increasing appetite for noninvasive therapeutic options are expanding the addressable patient base in ambulatory and home settings. This creates room for value propositions that reduce procedural burden while preserving clinical efficacy.

In Europe, Middle East & Africa, heterogeneous reimbursement landscapes and variable regulatory pathways require companies to localize evidence generation and pricing strategies. Some markets within this region have progressive reimbursement mechanisms that support innovative therapeutic devices when robust health-economic evidence is presented, while others remain price-sensitive and prefer lower-complexity devices with predictable cost profiles. Across procurement systems and clinical practice patterns, partnerships with regional distributors and clinical opinion leaders are instrumental in building credibility and facilitating market access.

Asia-Pacific presents a blend of rapid adoption among higher-income markets and rising demand in emerging economies. In many Asia-Pacific markets, the interplay between expanding private healthcare delivery and growing consumer healthcare literacy creates opportunities for both implantable and noninvasive devices. Nevertheless, manufacturers must navigate diverse regulatory requirements, local manufacturing expectations, and differing clinical practice patterns. Across all regions, strategic alignment between clinical evidence, reimbursement positioning, and distribution networks will determine the pace and scale of adoption.

Competitive dynamics and corporate strategies among established manufacturers, specialist innovators, and distribution partners that drive product portfolios, market entry, and clinical adoption

Competitive dynamics reflect a mixture of established medical device manufacturers, specialist innovators, and emerging technology providers. Leading companies leverage a combination of clinical evidence generation, product portfolio breadth, and channel partnerships to maintain traction in core markets. Key corporate strategies include iterative product development to reduce procedural complexity, material innovations that improve biocompatibility and longevity, and the cultivation of clinical champions through targeted investigator-initiated studies and real-world outcome registries.

Strategic collaborations and licensing agreements are common as firms seek to complement internal capabilities with external expertise in materials science, electronics, and therapeutic energy modalities. Companies that can integrate post-market service models-such as training programs, surgeon support, and product warranties-create sustainable differentiation that extends beyond the initial sale. Additionally, distribution strategies that blend direct hospital engagement with specialist retail and online channels improve access across diverse end-user contexts.

Mergers, acquisitions, and minority investments continue to be tools for capability acquisition and accelerated market entry, particularly when novel therapeutic mechanisms or digital health add-ons are involved. Firms that maintain transparency around clinical outcomes, invest in payer engagement, and adapt manufacturing footprints in response to trade policy shifts will likely secure competitive advantage. Ultimately, corporate success will be determined by the ability to align innovation pipelines with pragmatic commercialization plans and resilient supply chain architectures.

Practical and prioritized recommendations for manufacturers, clinicians, and channel partners to accelerate clinical adoption, strengthen market access, and mitigate commercial risk

Industry leaders should prioritize a set of pragmatic actions to convert insights into measurable commercial outcomes. First, invest in comparative clinical evidence and real-world registries that demonstrate device durability, functional outcomes, and complication profiles across primary, secondary, and mixed indications. Such evidence will be critical for convincing payors and clinicians, and for differentiating devices within hospital procurement processes. Second, diversify manufacturing and supplier networks to reduce exposure to tariff volatility and single-source dependencies, while documenting traceability and quality systems for regulatory submissions.

Third, tailor product portfolios and commercialization plans to specific demographic and clinical segments, recognizing that age group, etiology of dysfunction, and end-user setting materially influence device selection. Simultaneously, optimize material and mechanism choices to balance performance, cost, and regulatory risk. Fourth, develop hybrid channel strategies that combine hospital partnerships for complex procedures with online platforms and specialist retailers for less invasive solutions and patient education. Fifth, engage early with payors and health technology assessment bodies to align evidence generation with reimbursement criteria and to explore innovative payment models that reflect long-term value rather than upfront cost alone.

Finally, build adaptive commercial models that integrate clinician training, warranty and service offerings, and digital support tools to improve procedural outcomes and patient satisfaction. These steps will strengthen product positioning, reduce commercial friction, and accelerate sustainable adoption.

Transparent research methodology detailing data sources, expert validation, analytical frameworks, scenario testing, and acknowledged limitations to underpin robust device market insights

The research methodology underpinning this analysis combines primary and secondary data collection, a structured analytical framework, and iterative validation with clinical and commercial experts. Primary inputs include interviews with clinicians, procurement leaders, distributors, and technology developers to capture experiential insights on device performance, adoption barriers, and channel dynamics. Secondary sources comprise peer-reviewed clinical literature, regulatory guidance documents, materials science research, and publicly available policy analyses to triangulate clinical and safety evidence.

Analytical methods include segmentation mapping across product, indication, demographic, material, mechanism, power source, end-user, and distribution dimensions to identify high-opportunity intersections. Scenario analysis is used to stress-test supply chain and tariff impacts on operational continuity and procurement behavior. The methodology emphasizes transparency in assumptions, with sensitivity analyses performed where conclusions depend on variable inputs. Findings were iteratively validated with independent clinical advisors and industry practitioners to ensure practical relevance and to refine interpretive judgments.

Limitations of the methodology are acknowledged, including the variability of regional reimbursement environments and the evolving nature of clinical evidence for newer therapeutic modalities. Where appropriate, the report highlights data gaps and recommends priority evidence-generation activities to strengthen future assessments.

Concluding synthesis of market drivers, structural risks, and strategic priorities to inform executive decision-making, investment choices, and product roadmaps

In conclusion, the erectile dysfunction device landscape is at an inflection point where clinical innovation, material science, regulatory pragmatism, and channel evolution collectively shape strategic imperatives. Manufacturers that integrate robust evidence-generation with resilient manufacturing footprints and tailored channel strategies will be best placed to convert product innovation into sustainable commercial success. Attention to patient preferences, demographic trends, and indication-specific needs will further refine product-market fit and drive differentiated value propositions.

Regulatory clarity and payer engagement remain critical enablers for widespread adoption, particularly for higher-complexity implantable solutions and novel therapeutic modalities. The tariff environment and shifting distribution economics underscore the necessity for flexible supply chain architectures and transparent cost management strategies. Ultimately, success in this market will hinge on the ability to align clinical proof, operational resilience, and go-to-market execution in a way that delivers demonstrable outcomes for patients and predictable value for healthcare systems.

Organizations that adopt a disciplined, evidence-led approach to product development and commercialization will unlock opportunities across diverse geographies and care settings, positioning themselves for long-term leadership in a rapidly evolving therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of wearable neuromodulation devices for erectile dysfunction management
  • 5.2. Surging investment in home-use shockwave therapy units by consumer medical startups
  • 5.3. Emergence of personalized 3D-printed penile support and vacuum therapy accessories
  • 5.4. Integration of artificial intelligence diagnostics into at-home erectile dysfunction treatment
  • 5.5. Growing consumer demand for noninvasive electromagnetic stimulation solutions
  • 5.6. Advancements in smart PDE5 inhibitor transdermal patches for sustained patient compliance
  • 5.7. Expansion of digital health platforms offering virtual counseling and device tracking features
  • 5.8. Collaborations between urology clinics and telemedicine services to promote device accessibility
  • 5.9. Focus on eco-friendly and reusable materials in vacuum erection device manufacturing processes
  • 5.10. Adoption of blockchain for secure patient data management in erectile dysfunction devices

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Devices Market, by Product Type

  • 8.1. Penile Implants
    • 8.1.1. Inflatable Implants
    • 8.1.2. Semi-Rigid Implants
  • 8.2. Supportive Devices
    • 8.2.1. Clamping Devices
    • 8.2.2. Ring Constriction Devices
  • 8.3. Therapeutic Devices
    • 8.3.1. Low-Intensity Pulsed Ultrasound Devices
    • 8.3.2. Shockwave Therapy Devices
  • 8.4. Vacuum Constriction Devices

9. Erectile Dysfunction Devices Market, by Indication

  • 9.1. Mixed Erectile Dysfunction
    • 9.1.1. Aging-Related Causes
    • 9.1.2. Combination Causes
  • 9.2. Primary Erectile Dysfunction
    • 9.2.1. Neurological Causes
    • 9.2.2. Vascular Causes
  • 9.3. Secondary Erectile Dysfunction
    • 9.3.1. Hormonal Causes
    • 9.3.2. Psychogenic Causes

10. Erectile Dysfunction Devices Market, by Age Group

  • 10.1. 18-40 Years
  • 10.2. 41-60 Years
  • 10.3. 61 Years And Above

11. Erectile Dysfunction Devices Market, by Material Type

  • 11.1. Elastomeric
  • 11.2. Metallic
    • 11.2.1. Stainless Steel
    • 11.2.2. Titanium
  • 11.3. Polyurethane
  • 11.4. Silicone

12. Erectile Dysfunction Devices Market, by Mechanism of Action

  • 12.1. Hydraulic Action Devices
  • 12.2. Mechanical Action Devices

13. Erectile Dysfunction Devices Market, by Power Source

  • 13.1. Battery-Powered
  • 13.2. Manual

14. Erectile Dysfunction Devices Market, by End-User

  • 14.1. Home Healthcare
  • 14.2. Hospitals
  • 14.3. Specialty Clinics

15. Erectile Dysfunction Devices Market, by Distribution Channel

  • 15.1. Online Platforms
  • 15.2. Retail Pharmacies
  • 15.3. Specialist Retailers
    • 15.3.1. Medical Device Stores
    • 15.3.2. Surgical Supply Stores

16. Erectile Dysfunction Devices Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Erectile Dysfunction Devices Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Erectile Dysfunction Devices Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Advin Health Care
    • 19.3.2. Alma Lasers Ltd.
    • 19.3.3. Augusta Medical Systems LLC
    • 19.3.4. Boston Scientific Corporation
    • 19.3.5. Coloplast A/S
    • 19.3.6. Comphya SA
    • 19.3.7. DirexGroup
    • 19.3.8. Dornier MedTech GmbH
    • 19.3.9. Futura Medical Developments Limited
    • 19.3.10. G.SURGIWEAR LTD.
    • 19.3.11. Implantica Management AG
    • 19.3.12. Medispec Ltd.
    • 19.3.13. OHHMED Medical Ltd.
    • 19.3.14. Owen Mumford Limited
    • 19.3.15. PROMEDON GmbH
    • 19.3.16. Rigicon, Inc.
    • 19.3.17. STORZ MEDICAL AG
    • 19.3.18. T.E. Inc.
    • 19.3.19. TIMM Medical
    • 19.3.20. Vacurect
    • 19.3.21. Zimmer MedizinSysteme GmbH
    • 19.3.22. ZSI Surgical Implants S.R.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. ERECTILE DYSFUNCTION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. ERECTILE DYSFUNCTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ERECTILE DYSFUNCTION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SU